{"groups":[{"description":"Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).","id":"FG000","title":"Newly Diagnosed (ND) MM"},{"description":"Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).","id":"FG001","title":"Relapsed/Refractory (R/R) MM"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"8"}],"type":"Too ill to Participate"},{"reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"26"}],"type":"Patient declined participation and declined follow-up for survival"},{"reasons":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"58"}],"type":"Patient withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"}],"type":"Physician discretion"},{"reasons":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"62"}],"type":"Change in physician or transferred to another treatment center"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"26"}],"type":"On Hospice"},{"reasons":[{"groupId":"FG000","numSubjects":"474"},{"groupId":"FG001","numSubjects":"642"}],"type":"Deceased"},{"reasons":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"63"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"85"}],"type":"Due to study discontinued at site"},{"reasons":[{"groupId":"FG000","numSubjects":"1484"},{"groupId":"FG001","numSubjects":"937"}],"type":"Reason not Specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2338"},{"groupId":"FG001","numSubjects":"1915"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2193"},{"groupId":"FG001","numSubjects":"68"}],"comment":"The most common treatment regimens prescribed in participants treated in 1st line of therapy were proteosome inhibitor (PI)+ immunomodulatory drug (IMiD), PI+ alkylating agent (AA), and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","type":"1st Line of Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"928"},{"groupId":"FG001","numSubjects":"950"}],"comment":"The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","type":"2nd Line of Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"406"},{"groupId":"FG001","numSubjects":"1049"}],"comment":"The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and monoclonal antibody (mAB)+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","type":"3rd Line of Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"185"},{"groupId":"FG001","numSubjects":"727"}],"comment":"The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","type":"4th Line of Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"153"},{"groupId":"FG001","numSubjects":"767"}],"comment":"The most common treatment regimens prescribed in participants treated in \\>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","type":">4th Line of Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"93"}],"comment":"Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).","type":"Line of Therapy: Unknown"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2338"},{"groupId":"FG001","numSubjects":"1915"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Prospective data was collected for newly diagnosed multiple myeloma (NDMM) and Relapsed/Refractory multiple myeloma (RRMM) participants. Participants were also divided for analysis of some part of this study according to lines of therapy (LOT) they received. The final outcomes analysis performed at the end of study included 3263 participants excluding 990 participants from 4253 due to concerns around the robustness of data. Participants who received \\>1 LOT were counted more than once.","recruitmentDetails":"Participants took part in the study at 130 investigative sites in China, Taiwan, Belgium, France, Germany, Greece, Israel, Italy, Spain, Turkey, United Kingdom, Brazil, Colombia, Mexico, United States from 1 July 2016 to 30 September 2021. A total of 4253 participants were enrolled in this study."}